期刊文献+

晚期胆管癌立体定向放疗的临床分析

Analysis of clinical characteristics of SBRT treatment for 58 cases with cholangiocarcinoma
下载PDF
导出
摘要 目的:总结分析晚期胆管癌患者临床病理因素,观察立体定向放射治疗晚期胆管癌的近期疗效及生存时间,探讨立体定向放疗在晚期胆管癌治疗中的作用。方法:选择在海军总医院接受体部伽玛刀治疗的58例晚期胆管癌患者,对其临床资料进行回顾性分析。结果:随访率为100%,全组患者近期疗效评估:完全缓解(CR)8例,部分缓解(PR)30例,病情稳定(SD)15例,临床获益率(CBR)为91.4%。有11例患者发生Ⅰ-Ⅱ级胃肠道反应,主要表现为食欲下降、恶心及呕吐,发生率为19.0%,13例出现腹痛,发生率为22.4%;4例患者发生发热,发生率为6.8%。结论:体部伽玛刀是治疗晚期胆管癌的有效方式,不良反应可耐受。 Objective: We analyze the clinical and pathological factors in patients with advanced cholangiocarcinoma, summarize the efficacy and survival time of stereotactic radiotherapy for advanced cholangiocarcinoma and explore the efficacy of stereotactic radiotherapy. Methods: From January 2006-2012,total 58 patients in our hospital were treated by body gamma knife, all patients were given body gamma knife governance. Results: The follow-up rate was 100%, the efficacy of whole group of patients were assessed,with CR 8 cases, PR 30 cases, SD 15cases, clinical benefit rate was 91.4%, Adverse reactions included gastrointestinal reactions of 11 cases,mainly as appetite, nausea, vomiting, by incidence rate of 19.0%, abdominal pain of 13 cases, by the incidence of 22.4%, fever occurred in 4 patients, the rate was 6.8%. Conclusion: Body gamma knife is an effective treatment for advanced cholangiocarcinoma,and adverse reactions can be tolerated.
出处 《中国医学装备》 2014年第6期118-121,共4页 China Medical Equipment
关键词 胆管细胞癌 立体定向放疗 体部伽玛刀 Cholangiocarcinoma Stereotactic radiotherapy Gamma knife
  • 相关文献

参考文献25

  • 1Daines WP,Rajagopalan V,Grossbard ML,et al.Gallbladder and biliary tract carcinoma:A comprehensive update,Part 2[J].Oncology(Williston Park), 2004, 18(8): 1049-1059.
  • 2Endo I, Gonen M, Yopp A C,et al. Intrahepatic cholangiocarcinoma : rising fequency, improved survival,and determinants of outcome after resection[J]. Ann Surg, 2008,248(1): 84- 96.
  • 3Ben-Josef E,Normolle D,Ensminger WD,et al.Phase II trial of high-dose conforrnal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies[J].J Clin Oncol, 2005,23(34). 8739-8747.
  • 4Anderson CD,Pinson CW,Berlin J,et al.Diagnosis and treatment of cholangiocarcinoma[J]. Oncologist, 2004,9(1): 43-57.
  • 5Khan SA,Toledano MB,Taylor-Robinson SD.Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma[J].HPB(Oxford),2008, 10(2). 77-82.
  • 6E1-Serag HB, Engels EA, Landgren O, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection..A population-based study of U.S.veterans[J]. Hepatology, 2009, 49(1). 116-123.
  • 7Lee TY,Lee SS, Jung SW,et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea.a case-control study[J].Am J Gastroe nterol, 2008,103(7). 1716-1720.
  • 8DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma .. thirty-one- year experience with 564 patients at a single institution[J]. Ann Surg, 2007,245(5).. 755-762.
  • 9Nakanuma Y, Xu J, Harada K, et al. Pathological spectrum of intrahepatic cholangiocarcinoma arising in non-biliary chronic advanced liver diseases[J]. Pathol Int, 2011,61 (5) : 298-305.
  • 10Patel AH,Hamois DM,Klee GG,et al.The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis[J]. Am J Gastroenterol,2000,95(1):204-207.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部